The covid-19 pandemic put China’s health care sector back in the spotlight. We believe there are many reasons to be upbeat about the sector’s future growth beyond the pandemic. READ MORE
Similar Posts:
- Variant View: China’s Zero-COVID Policy is Dead (Asian Century Stocks Substack)
- Health Care: The Next Wave of Innovation in China (Franklin Templeton)
- China Will Not Be Able To Offset Its Property Bubble Easily (Daniel Lacalle)
- Asia & China Equities – Outlook in 3-D: Domestic, Digitalisation, Diversification (BNP Paribas)
- Emerging & Global Markets Catch Up With Reality (Krane Shares)
- Global Emerging Markets: Country Allocation Review 2021 (Federated Hermes)
- China: Innovation Superpower (Wellington Management)
- Reshaping Supply Chains Away From China (The Asset)
- 2021 Midyear Asia Economic Outlook: Divergent Recoveries (PineBridge Investments)
- China beyond Evergrande: Contagion or containment? (PineBridge Investments)
- Capitalizing on USA-China Tensions (Stock Spotlight Substack)
- Narayana Hrudayalaya (NSE: NH / BOM: 539551): Has Profitably Mastered the Affordable Health Care Business Model
- Does the End of China’s Love Affair With Property Spell Heartbreak for Investors? (Federated Hermes)
- China Venture Capital Deals Shrink Amid Regulatory Concerns (Nikkei Asia)
- Five Takes on Multi-asset Investing in Post-Pandemic China (Schroders)
